MedTrace Logo

Treatment of Leishmaniasis With Impavido® (Miltefosine): Higher-Weight Patient Registry

NCT02429505 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2020-08-28

No results posted yet for this study

Summary

This study is a prospective observational study in which patients undergoing treatment for leishmaniasis with miltefosine (Impavido) in the US and who weigh \> 75 kg can volunteer to provide information about their clinical response to treatment up to 6 months after the start of treatment.

Conditions

  • Leishmaniasis

Interventions

DRUG

Miltefosine

miltefosine: target 2.5 mg/kg/day for 28 days

Sponsors & Collaborators

  • Knight Therapeutics (USA) Inc

    lead INDUSTRY

Principal Investigators

  • Janet Ransom, PhD · Fast Track Drugs and Biologics LLC

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2020-03-31
Completion
2020-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02429505 on ClinicalTrials.gov